Form 4 Filing for 4D Molecular Therapeutics, Inc.

This filing details stock transactions by Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, Inc. On September 1, 2026, Bizily acquired 584 shares of Common Stock at $6.49 per share and disposed of 584 shares at $14.00 per share, resulting in 8617 shares held. Additionally, a stock option to buy 584 shares of Common Stock was exercised and disposed of, with the underlying shares valued at $0.00. The option, with an exercise price of $6.49, has a post-transaction share count of 2959. These transactions were made under a 10b5-1 trading plan. The shares underlying the stock option vest monthly, with full vesting occurring four years from the Vesting Commencement Date of June 16, 2022, provided the individual remains a service provider.